GO
Loading...

Mylan Inc

More

  • Is patriotism a virtue in business? Friday, 18 Jul 2014 | 7:00 AM ET

    Do US firms have a duty to sacrifice their own interests for the broader good of the country?, asks law professor Dan Eaton.

  • July 16- Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday as demand for its recently-recalled infant formulas began to recover and profit margins improved for other business segments.

  • Sanofi mulls selling mature drug portfolio: Report Wednesday, 16 Jul 2014 | 8:39 AM ET

    Sanofi talked with Abbott Laboratories, Mylan and private equity firms over selling a portfolio of mature drugs, according to a document.

  • Jack Lew pushes for crackdown on tax inversions Wednesday, 16 Jul 2014 | 6:19 AM ET
    Jack Lew, U.S. Treasury Secretary.

    Treasury Secretary Jack Lew has urged Congress to crack down on merger deals in which companies seek to relocate overseas to cut US taxes.

  • How US drug firms plan to evade taxes Tuesday, 15 Jul 2014 | 5:35 AM ET

    Increasingly, drug makers and medical device companies have found a way to self-medicate when it comes to taxes and regulation.

  • *Citigroup to pay $7 bln to settle U.S. mortgage probe. NEW YORK, July 14- U.S. stocks ended higher on Monday, with the Dow Jones industrial average hitting an intraday record, lifted by Citigroup's better-than-expected earnings and more deals in the healthcare space. Citigroup Inc shares jumped 3 percent to $48.42 and gave the S&P 500 one of its biggest boosts.

  • Stocks end higher on M&A; Dow sets intraday record Monday, 14 Jul 2014 | 4:50 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks climbed on Monday, with the S&P 500 bouncing back from weekly losses, after Citigroup's earnings beat estimates.

  • *Citigroup to pay $7 bln to settle U.S. mortgage probe. NEW YORK, July 14- U.S. stocks rose on Monday with the Dow Jones industrial average hitting a new intraday high, lifted by better than expected earnings from Citigroup and more deals in the healthcare space.

  • July 14- Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.

  • *Citigroup up after earnings, settlement. NEW YORK, July 14- U.S. stocks rose on Monday, sparked by the latest flurry of merger activity and earnings from Citigroup, putting the S&P 500 on pace to climb for a second straight session.

  • Big shale deal may be easy money or strong market Monday, 14 Jul 2014 | 10:03 AM ET
    Traders on the floor of the New York Stock Exchange.

    Big mergers are afoot. But is a major shale oil deal a sign of a strong market?

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • NEW YORK, July 14- U.S. stocks were poised for a higher open on Monday after the latest flurry of merger activity and earnings from Citigroup, putting the S&P 500 on track to rebound from its worst weekly decline since April.

  • Mylan in $5.3B deal for Abbott's generics assets Monday, 14 Jul 2014 | 8:47 AM ET

    Mylan said it would buy Abbott Labs' generics business outside the United States in an all-stock transaction valued at about $5.3 billion.

  • Early movers: C, AAPL, MYL, BID, EBAY, GE & more Monday, 14 Jul 2014 | 8:06 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures higher on M&A after down week Monday, 14 Jul 2014 | 7:40 AM ET

    *Shire accepts Abbvie takeover offer. *London- listed drugmaker Shire Plc succumbed to an increased 31 billion pounds takeover offer from Abbvie Inc, ending a long-running courtship largely motivated by tax rates. U.S.-listed shares of Shire rose 2.4 percent to $255.10 while Abbvie shed 0.7 percent to $54.56 in premarket trade.

  • July 14- Generic drugmaker Mylan Inc said it would buy Abbott Laboratories' specialty and branded generics business in developed markets outside the United States in an all-stock transaction valued at about $5.3 billion.

  • July 14- Generic drugmaker Mylan Inc said it would buy Abbott Laboratories' specialty and branded generics business outside the United States in an all-stock transaction valued at about $5.3 billion.

  • *AbbVie raises bid to 53.20/ share from 51.15. *Bid comprises 24.44 stg cash and 0.8960 new AbbVie shares. LONDON, July 14- London- listed drugmaker Shire Plc succumbed to an increased 31 billion pounds takeover offer from Abbvie Inc on Monday, signaling the conclusion to a long-running courtship largely motivated by tax.

  • Mylan nears major deal for Abbott drugs: Sources Friday, 11 Jul 2014 | 6:42 PM ET

    U.S. generic drugmaker Mylan is said to be in advanced talks to buy a multibillion-dollar portfolio of established products from Abbott Laboratories.